HeartSciences Inc. (NASDAQ:HSCS) Shares Shorted: Short Interest Down 65.1% in September

HeartSciences Inc. (NASDAQ:HSCS) was the target of a large decrease in short interest during the month of September. As of September 15th, there was short interest totaling 39,859 shares, a decrease of 65.1% from the August 31st total of 114,152 shares. Currently, 0.9% of the shares of the stock are sold short. Based on an average daily volume of 131,326 shares, the short-interest ratio is presently 0.3 days.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Wall Street Zen raised HeartSciences from a “sell” rating to a “hold” rating in a research note on Sunday, September 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of HeartSciences in a research report on Monday, September 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $8.00.

HeartSciences Stock Down 6.9%

NASDAQ:HSCS traded down $0.30 during trading hours on Tuesday, reaching $4.12. The company had a trading volume of 128,918 shares, compared to its average volume of 808,236. HeartSciences has a twelve month low of $1.63 and a twelve month high of $5.25. The firm has a market cap of $19.80 million, a price-to-earnings ratio of -1.28 and a beta of 1.85. The business’s 50-day simple moving average is $3.05 and its two-hundred day simple moving average is $2.51.

HeartSciences (NASDAQ:HSCS) last issued its earnings results on Monday, September 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.14). The company had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.10 million. As a group, equities analysts predict that HeartSciences will post -2.99 earnings per share for the current year.

HeartSciences Company Profile

HeartSciences, Inc is a medical technology company focused on improving the detection and management of cardiovascular disease. The company develops electrocardiography (ECG) technologies intended to provide clinicians with additional information about cardiac function using a test that is widely available in healthcare settings.

Its principal technology is the MyoVista wavECG system, which applies proprietary signal-processing methods, including wavelet analysis, to standard 12-lead ECG data.